Breast Cancer

Utilizing an artificial intelligence–assisted workflow to detect sentinel lymph node metastases in patients with breast cancer was deemed safe according to current diagnostic standards and reduced the need for immunohistochemistry and its associated financial burden.

The combination of ribociclib and endocrine therapy led to an improvement in progression-free survival and overall survival vs placebo plus endocrine therapy in patients with hormone receptor-positive/HER2-negative advanced breast cancer across all age groups.

In this final episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, shed light on clinical outcomes following surgery of the primary tumor in patients with stage IV breast cancer.

Paolo Tarantino, MD, discusses ongoing investigations into the use of antibody-drug conjugates targeting B7-H4 vedotin, highlighting their potential significance for the treatment paradigm in breast cancer.

Erica L. Mayer, MD, MPH, discusses findings from research investigating CDK4/6 inhibitors in patients with hormone receptor (HR)–positive, HER2-negative breast cancer.

The expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.

Joseph A. Sparano, MD, FACP, discusses developments in breast cancer diagnosis and treatment.

The FDA has granted fast track designation to zotatifin for use in combination with fulvestrant and abemaciclib as second- or third-line therapy for the treatment of patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with disease progression following treatment with endocrine therapy and a CDK4/6 inhibitor.

With multiple antibody drug conjugate options now available for patients with HER2-negative metastatic breast cancer, clinicians must consider a variety of factors when selecting and sequencing therapies.

In this fourth episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, discuss how to appropriately manage patients with stage IV breast cancer and outline when surgical approaches may be appropriate for this population.

Hope Rugo, MD reviews key data from the CAPItello-291 phase 3 trial recently presented at the San Antonio Breast Cancer Symposium in December 2022.

Mylin A. Torres, MD, discusses using antibody-drug conjugates (ADCs) to treat patients with breast cancer.

Cynthia Ma, MD, PhD, discusses the use of AKT inhibitors vs PI3K inhibitors in breast cancer.

Experts in breast, lung, and gastric malignancies provide insights on multidisciplinary care in oncology and educating community specialists.

Medical oncologists discuss prospects and challenges in the breast and lung cancer treatment landscapes.

Joseph Gligorov, MD, emphasizes the impact of trastuzumab deruxtecan in HER2-positive breast cancer and explores its potential in HER2-low populations, and envisions a future where ADCs and immunotherapy will have a vital role in treatment, particularly in triple-negative breast cancer.

In this third episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, discuss key advancements made in the surgical treatment of patients with breast cancer.

The FDA has approved the FoundationOne® CDx for use as a companion diagnostic to identify patients with advanced hormone receptor–positive, HER2-negative advanced breast cancer who may be eligible for treatment with the combination of capivasertib and fulvestrant.

Kevin Kalinsky, MD, MS, discusses key takeaways from the 2023 Bridging the Gaps in Breast Cancer meeting, highlighting questions that continue to persist in the treatment of breast cancer.

Reva K Basho, MD, discusses the use of antibody-drug conjugates across the spectrum of breast cancer subtypes at the 2023 Bridging the Gaps in Breast Cancer meeting.

Specialists in gastric cancer look to the future treatment landscape and review ongoing research in the disease space.

Clinical insights on best practices for treating patients with TROP2-targeted therapy.

The FDA has approved capivasertib plus fulvestrant for the treatment of patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alterations, following progression on at least 1 endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.

Dr Joseph Gligorov discusses the management of brain metastases in patients with HER2-positive breast cancer, emphasizing tucatinib and trastuzumab as promising options.

Joseph Gligorov, MD, discusses the potential side effects of second- and third-line therapies for patients with HER2+ metastatic breast cancer and highlights the low-toxicity profile of tucatinib when combined with trastuzumab and capecitabine.